SHIELD Study: Using Naso-oropharyngeal Antiseptic Decolonization to Reduce COVID-19 Viral Shedding (SHIELD)
COVID-19, SARS-CoV 2
About this trial
This is an interventional prevention trial for COVID-19 focused on measuring COVID-19, povidone-iodine, chlorhexidine gluconate, transmission, virology
Eligibility Criteria
Inclusion Criteria:
- Participant is a essential worker performing at least some in-person job duties (not 100% remote)
- Participant is willing and able to perform intervention and data collection procedures.
- Participant is able to provide informed consent in English language.
Exclusion Criteria:
- Diagnosis of COVID-19 within 2 months prior to enrollment, or active respiratory illness symptoms at time of enrollment
- Known medical contraindication to chlorhexidine gluconate or povidone-iodine treatment ingredients (such as a known allergy)
- Participant has a known medical and/or surgical reason prohibiting nasal swab sampling.
- Participant is female who is pregnant, or believes she may be pregnant, at time of enrollment.
- Participant is actively taking/using any treatments or interventions as part of any other COVID-19 related investigational trials.
Sites / Locations
- University of Wisconsin-Madison
Arms of the Study
Arm 1
Arm 2
Other
Other
Control > Active Intervention
Active Intervention > Control
Treatment is 3 weeks of standard personal protective equipment without any povidone-iodine (PI) or chlorhexidine gluconate (CHG) intervention (control), followed by a 2 weeks washout period, and 3 weeks of nasal (10% povidone-iodine swab sticks in each nostril) and CHG oral decolonization (swish and spit 15 ml 0.12% CHG oral rinse for 30 seconds, four times/day) procedures.
Treatment is 3 weeks of nasal (10% povidone-iodine swab sticks in each nostril) and CHG oral decolonization (swish and spit 15 ml 0.12% CHG oral rinse for 30 seconds, four times/day) procedures, followed by 2 weeks of washout, and 3 weeks of standard personal protective equipment without any PI or CHG intervention (control).